Risk of osteoporosis in patients with chronic inflammatory neuropathy- a population-based cohort study

Abstract

The risk of osteoporosis in patients with chronic inflammatory neuropathy (CIN) has not been evaluated in detail. We conducted a population-based case-control study nested in a retrospective cohort to analyze osteoporosis risk among patients with CIN using a nationwide database. Patients with CIN based on the Korean Classification of Disease diagnostic code were included and were matched to controls. A Cox proportional hazards regression model was used to evaluate the effect of CIN on osteoporosis. After propensity score matching, 585 CIN patients and 585 controls were selected. Patients with CIN had an increased osteoporosis risk (hazard ratio [HR] = 2.293, 95% confidence interval [CI] 1.460–3.601) compared with controls. The osteoporosis risk was higher among male patients with CIN than among male controls (HR = 5.404, 95% CI 2.252–12.969), while there were no significant differences among women. Among the CIN patients, the average daily dose of corticosteroids was higher in those who developed osteoporosis (19.6 mg [10.8–49.3]) than those who did not (16.2 mg [7.2–29.1], p = 0.001). The osteoporosis risk among CIN patients is higher than among controls. High risk of osteoporosis in male patients may indicate that osteoporosis in CIN patients results from the disease itself or related treatments.

Is diabetes mellitus a risk factor for low bone density: a systematic review and meta-analysis

“…Sensitivity analysis revealed that after excluding 8 studies [ 26 , 32 , 33 , 35 – 37 , 39 , 41 ], the results still remained the same (11 studies, n = 25,861, OR = 1.05, 95% CI = [0.91, 1.20], P = 0.52).…”

“…After examining the titles and abstracts, 3013 articles were excluded. After reviewing the full-texts of the remaining 774 articles, 3 studies were excluded due to sample size smaller than 100, 2 studies were excluded due to repeated publications, 750 studies were excluded as diabetes mellitus was not investigated, and 5 studies were excluded because no information is given about BMD [ 28 – 32 ]. Finally, 14 relevant studies were included in this systematic review [ 33 – 46 ] (Fig.…”

Probucol promotes osteoblasts differentiation and prevents osteoporosis development through reducing oxidative stress

“…Estrogen absence results in postmenopausal osteoporosis, inducing elevated bone metabolism and ultimately forfeiting bone trabecular connectivity and cortical osteoporosis (Ma et al 2019 ). It is estimated that the number of women over the age of 50 with osteoporosis is about twice that of men (Kim et al 2019 ). Its pathogenesis involves dysregulated interactions between osteoblasts and osteoclasts, leading to bone formation and resorption imbalance (Cheng et al 2019 ).…”